CDC Delays Release of Report on COVID Vaccine Benefits

The acting director of the Centers for Disease Control and Prevention has blocked publication of a report showing COVID-19 vaccines reduced emergency department visits and hospitalizations for healthy adults by approximately 50%, according to the Washington Post [1]. The report had already cleared the agency's internal scientific review process. Its delay is the latest in a series of disruptions to the CDC's public health publishing apparatus that began in January 2025 and has accelerated throughout the current administration.

What the Report Found

The shelved study examined COVID-19 vaccine effectiveness during the 2025–2026 winter respiratory season. It found that vaccination cut the likelihood of emergency department visits by about 50% and hospitalizations by approximately 55% among healthy adults, compared to unvaccinated individuals [1][2]. The study used observational methods — the same approach the CDC has relied on for years to assess flu vaccine effectiveness and that underpinned a widely cited 2021 New England Journal of Medicine study on COVID vaccine performance [3].

For context, previously published CDC data from the 2024–2025 season — using the same VISION and IVY surveillance networks — found vaccine effectiveness of 33% against COVID-associated emergency department and urgent care visits among adults 18 and older, and 45–46% against hospitalizations among immunocompetent adults 65 and older [4]. The delayed report's higher effectiveness estimates for the 2025–2026 formulation would represent a meaningful improvement over those earlier figures.

Who Delayed It and Why

Jay Bhattacharya, the NIH director who has simultaneously served as acting CDC director since February 2026, ordered the delay [1][5]. Bhattacharya took over the CDC after Jim O'Neill's tenure as acting director hit the 210-day limit under the Vacancies Reform Act [5].

An HHS spokesperson said Bhattacharya had concerns about "the observational method used in the study to calculate vaccine effectiveness" and wanted to ensure "the paper uses the most appropriate methodology for such a study" [1][2]. The spokesperson characterized this as routine: "It's routine for CDC leadership to review and flag concerns about MMWR papers, especially relating to their methodology" [2].

Bhattacharya, a Stanford health economist, became prominent during the pandemic as a co-author of the Great Barrington Declaration, which opposed lockdowns and favored a "focused protection" approach. He has publicly stated he supports vaccination but has voiced skepticism about certain COVID vaccine mandates and the quality of observational studies used to measure vaccine effectiveness [6].

The Methodological Debate

HHS officials described the observational method as "predisposed to bias" because it focused on hospitalized patients rather than the broader population [2]. This is a recognized limitation of test-negative design studies — the standard approach used in the delayed report — which compare vaccination rates among patients who test positive for a disease with those who test negative but present similar symptoms.

Dan Jernigan, a former CDC vaccine safety official, countered that this real-world approach remains appropriate for tracking vaccine performance and has been the agency's standard methodology for respiratory virus vaccines for years [2]. The CDC used identical methods to produce annual flu vaccine effectiveness estimates that informed clinical recommendations without drawing leadership-level objections [4].

An independent review published in ScienceDirect in 2025 did raise broader concerns about the quality of evidence underlying COVID booster recommendations, noting that "assessments of the protection level provided by COVID-19 vaccines and especially seasonal boosters against severe outcomes (hospitalization, ICU, death, long-COVID) are based on very low-quality data and analyses" [7]. This critique, however, was directed at the field's overall evidence base, not specifically at the delayed report's design.

The tension between these positions reflects a genuine scientific disagreement. Observational studies are inherently less rigorous than randomized controlled trials. But randomized trials of seasonal vaccine updates are rarely conducted because they are expensive, slow, and ethically complicated when a vaccine is already recommended. Observational data is what the public health system has to work with in near-real time.

A Pattern of Disruption at the MMWR

The delay did not occur in isolation. The CDC's Morbidity and Mortality Weekly Report — the 73-year-old journal that serves as the primary vehicle for the agency's scientific communications — has faced unprecedented interference since January 2025.

In the earliest days of the second Trump administration, a communications pause across HHS prevented the MMWR from publishing on schedule for the first time in its history, with the January 23 and January 30, 2025 editions missing their publication dates [8][9]. When publication resumed on February 6, 2025, the first articles covered health risks from the Los Angeles wildfires — published days after President Trump had publicly criticized California Governor Gavin Newsom's fire response [9].

Three completed bird flu studies were stalled for weeks as the H5N1 virus continued spreading through poultry farms and dairy herds [9]. These studies covered findings on pet cats owned by infected dairy workers, wastewater testing results, and antibody testing of cow veterinarians [9].

Charlotte Kent, the MMWR's editor-in-chief, departed in February 2025 after administration officials pressured the journal to change its reporting methods [10]. Then in October 2025, the MMWR stopped publishing entirely during a government shutdown, and editorial staff were laid off — though some were reinstated hours later [8][10].

A former health official told CBS News: "The MMWR has lost its autonomy" [9].

The ACIP Overhaul

The report delay also occurred against the backdrop of HHS Secretary Robert F. Kennedy Jr.'s June 2025 decision to remove all 17 members of the Advisory Committee on Immunization Practices (ACIP) and replace them with new appointees [11][12]. Kennedy, a longtime vaccine skeptic, described the move as necessary to "reestablish public confidence in vaccine science" [11].

Among the new appointees was Robert W. Malone, a physician-scientist who has promoted skepticism of mRNA vaccines, and Vicky Pebsworth, a regional director of the National Vaccine Information Center, an organization that has historically opposed vaccine mandates [12]. A U.S. District Judge later concluded that ACIP had been unlawfully reconstituted [11].

Jernigan, the former CDC official, drew a direct line between the ACIP changes and the report delay: "The secretary has already taken steps to try and remove the availability of the vaccine from children and others, so if you're putting out an MMWR that the vaccine is effective... that message is not in line with the direction you've been taking" [2].

Vaccine Uptake Is Already Declining

The information gap arrives at a time when COVID-19 vaccine uptake among American adults is falling.

Source: CDC COVIDVaxView

Data as of Jan 15, 2026CSV

As of January 2026, only 16.1% of adults 18 and older had received a 2025–2026 COVID-19 vaccine, down from 21% during the 2024–2025 season and 22.5% during the 2023–2024 season [13]. The decline is steeper among seniors.

Source: CDC COVIDVaxView

Data as of Jan 15, 2026CSV

Among adults 65 and older — the group at highest risk for severe COVID outcomes — uptake dropped to 30.8% in the current season from 49% the prior year [13][14]. COVID-19 hospitalization rates for adults 65 and older reached 824.8 per 100,000 during the 2023–2024 season, far exceeding rates in younger age groups [15]. In nursing homes, facilities with low vaccination uptake saw approximately 10% more COVID cases and roughly two-thirds more COVID hospitalizations compared to high-uptake facilities [16].

A sustained gap in CDC vaccine-benefit communications could accelerate these trends. The elderly, immunocompromised, and uninsured — groups that depend most heavily on public health guidance rather than private physician consultations — face the greatest exposure from delayed or suppressed efficacy data.

Outside Efforts to Fill the Gap

The disruption to CDC publishing has prompted independent institutions to create alternatives. In October 2025, the New England Journal of Medicine and the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota announced they would begin publishing "public health alerts" as a free substitute for MMWR content [10][17].

"[The alerts] will basically serve to be a way to convey the information that once was shared in the MMWR with all of us in a very timely way," said CIDRAP director Michael Osterholm [10]. Over 65 foundations have pooled resources to support independent scientific infrastructure during this period [10].

CIDRAP also created the Vaccine Integrity Project in April 2025, which began producing its own vaccine evidence reviews after the ACIP reconstitution [10]. These independent reviews have filled some of the gap left by the CDC, but they lack the institutional authority and data access that comes with federal agency publishing.

FOIA Requests and Legal Pressure

Separately, Freedom of Information Act requests have revealed tensions over vaccine data transparency at HHS agencies. Documents obtained by Children's Health Defense through litigation showed that CDC researchers revised a major COVID-19 vaccine study before publication in The Lancet Infectious Diseases in 2022, with key findings on reported deaths moved from prominent sections to supplementary materials [18]. The organization's senior research scientist described the changes as editing "to promote safety and to de-emphasize death" [18].

Dr. Tom Shimabukuro, the former director of the CDC Immunization Safety Office and an author of the Lancet study, was referred to the Department of Justice and the FBI's Office of Inspector General by Senator Ron Johnson in April 2025 for allegedly deleting records related to COVID-19 vaccine adverse events [18].

In a separate but related matter, a group of over 30 professors and scientists from Yale, Harvard, UCLA, and other universities filed a FOIA request for data the FDA used to license Pfizer's COVID-19 vaccine. The FDA initially stated it could take 55 years to process the roughly 329,000 pages of records, before a federal judge ordered accelerated release [19][20].

These cases reflect longstanding frustrations — predating the current administration — with the pace and completeness of federal vaccine data disclosures. They also provide ammunition for those who argue the CDC's publishing process has historically lacked transparency, complicating the narrative that the current delay is purely political.

How Allied Nations Handle Vaccine Data

The UK's Health Security Agency (UKHSA) publishes national flu and COVID-19 surveillance reports on a weekly basis, with vaccine effectiveness data included in regular editions available on gov.uk [21][22]. The European Centre for Disease Prevention and Control (ECDC) publishes vaccination coverage reports for all EU/EEA member states on a regular schedule [23]. Canada's Public Health Agency of Canada (PHAC) similarly releases vaccine surveillance data through its routine reporting systems.

In all three cases, vaccine effectiveness data flows through established publication pipelines without requiring sign-off from agency heads on individual studies. The UKHSA has specifically described its commitment to regular, transparent publication of vaccine effectiveness data as central to maintaining public confidence [21].

The U.S. system, by contrast, now requires political appointees to approve individual MMWR articles — a structural change that has no clear parallel among allied health agencies.

The Steelman Case for Delay

Defenders of additional review point to real instances where premature or poorly contextualized CDC publications created problems. During the early pandemic, shifting guidance on masking and the virus's transmissibility eroded public trust. The agency's initial messaging about breakthrough infections in vaccinated individuals was widely seen as confusing. And the broader concern that observational studies can overstate vaccine benefits — particularly when the vaccinated population differs systematically from the unvaccinated in health-seeking behavior — is shared by mainstream epidemiologists, not only political appointees [7].

If the delayed report's methodology genuinely produces inflated effectiveness estimates, publishing it could set the stage for public disappointment and further erode trust when updated data arrives. The HHS spokesperson's framing — that Bhattacharya wants "the most appropriate methodology" — is, on its face, a defensible position for any agency head.

Critics respond that the methodology in question is the same one the CDC has used for years without triggering leadership-level intervention, and that the timing — amid broader efforts to minimize vaccine promotion — makes the methodological objection difficult to take at face value [2][3]. They also note that delaying data while vaccine uptake declines has its own costs, and that methodological disagreements are normally resolved through published commentary and peer review, not by shelving completed work.

What Comes Next

No timeline has been announced for the report's release. It remains unclear whether the report will be published in revised form, returned for additional analysis, or quietly abandoned. The broader question — whether the CDC's scientific publishing apparatus can function independently under its current leadership structure — extends well beyond any single report.

The creation of NEJM-CIDRAP public health alerts, the Vaccine Integrity Project, and various FOIA-driven transparency efforts suggest that the scientific community is not waiting for the federal government to resume normal operations. Whether these ad hoc alternatives can substitute for the institutional credibility and data infrastructure of the CDC remains an open question — one with real consequences for the Americans who depend on public health guidance to make decisions about their care.